Q-omics provides the consensus-scored MIR450B profile across patient tissues and cancer cell-line models. MIR450B expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MIR450B is differentially expressed in 3, with the highest sampling consensus in UCEC. Additionally, MIR450B RNA expression shows 5,295 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, UCEC, and STAD as cancer lineages where MIR450B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR450B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR450B survival associations across molecular data types. MIR450B RNA expression shows survival associations in the most cancer types (14), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR450B RNA expression–survival associations across cancer types. High MIR450B expression shows unfavorable associations in KIRP, LUSC, BRCA, UCS and SKCM, but favorable associations in ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MIR450B RNA expression.
This table summarizes MIR450B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR450B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR450B shows lower tumor expression in UCEC, KICH and BRCA. The UCEC box plot shows higher MIR450B RNA expression in normal versus tumor tissue (log2 FC = −0.339, t-test p = .010).
This table shows molecular features associated with MIR450B in patient tissues and cancer cell lines. In patient samples, MIR450B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
